APIMEDS PHARMACEUTICALS US, INC. Earnings Per Share (Basic)
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Earnings Per Share (Basic) of -$11.77 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$11.77.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$2.26.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.09.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.14.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for fiscal 2025 was -$0.55.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for fiscal 2024 was -$0.18.
- APIMEDS PHARMACEUTICALS US, INC. earnings per share, basic for fiscal 2023 was -$0.17.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.77 10-Q · filed 2026-08-14 | -$33.83 10-Q · filed 2026-08-14 | -$5.67 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$5.49 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2026-03-31 | -$2.26 10-Q · filed 2026-05-26 | -$2.58 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$2.80 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$3.90 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.55 10-K · filed 2026-05-04 | ||
| 2025-09-30 | -$0.14 10-Q · filed 2025-11-12 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.47 10-Q · filed 2025-11-12 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-06-30 | -$2.57 10-Q · filed 2026-08-14 | -$0.26 10-Q · filed 2025-08-19 | -$3.35 10-Q · filed 2026-08-14 | -$0.33 10-Q · filed 2025-08-19 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-03-31 | -$0.05 10-Q · filed 2026-05-26 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2024-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.18 10-K · filed 2026-05-04 | ||
| 2024-09-30 | -$0.04 10-Q · filed 2025-11-12 | -$0.10 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.14 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$0.06 10-Q · filed 2025-08-19 | -$0.09 10-Q · filed 2025-08-19 | ||||
| 2024-03-31 | -$0.04 10-Q · filed 2025-05-20 | |||||
| 2023-12-31 | -$0.17 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |